• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Avraham Pharmaceuticals

edit

Avraham Pharmaceuticals (“Avraham”) is a privately held, emerging pharmaceutical company developing novel products for treatment and/or prevention of neurodegenerative disorders. Founded in 2010, Avraham has raised $9 million to conduct a European Phase II proof-of-concept efficacy trial in patients with Alzheimer’s disease, supporting the development of its lead product candidate, ladostigil.

Recent Milestones

edit

• 
  Avraham Pharmaceuticals received $5.7M in Private Equity funding. (2/21/13)
  Posted 2/21/13 at 7:20pm via finsmes.com
• 
  Avraham Pharmaceuticals received $3M in Venture Round funding. (11/14/11)
  Posted 11/14/11 at 6:44pm via finsmes.com
• 
  Avraham Pharmaceuticals received $9M in Series A funding. (7/13/10)
  Posted 7/13/10 at 5:33pm via onbiovc.com
• 
  Avraham Pharmaceuticals added David Warshawsky as CEO.
  Posted 7/13/10 at 5:33pm

Videos

Screenshots

edit

Sources

1. Avraham Pharmaceuticals, Ltd.: Series A $9M (onbiovc.com) [edit]
2. Avraham Pharmaceuticals Closes $3M Financing (finsmes.com) [edit]
3. Avraham Pharmaceuticals Raises $ 5.7M in Funding (finsmes.com) [edit]